Quaratusugene Ozeplasmid (Reqorsa) and Atezolizumab Maintenance Therapy in ES-SCLC Patients

חו"ל (דורש נסיעה)מגייס משתתפיםPHASE1, PHASE2

מצבים רפואיים

Small Cell Lung Cancer Extensive Stage

סיכום בשפה פשוטהבעזרת בינה מלאכותית

הסיכום נכתב על־ידי מודל שפה והוא ניסיוני. המידע עלול להיות חלקי או שגוי ואינו תחליף לייעוץ רפואי.

מיקומים
  • Rocky Mountain Cancer Centers, LLP, Lone Tree, Colorado, United States

    Contact: Study coordinator (Jennifer Hege) · jennifer.hege@usoncology.com
    Contact: Principal Investigator (Robert M Jotte, MD)
  • Washington University School of Medicine - Siteman Cancer Center, St Louis, Missouri, United States

    Contact: Study coordinator (Medical Oncology Clinical Call Center) · MedicalOncologyClinicalCallCenter@dom.wustl.edu · 314-747-1171
    Contact: Principal Investigator (Daniel Morgensztern, MD)
  • Gabrail Cancer Center Research, Canton, Ohio, United States

    Contact: Study coordinator (Carrie Smith) · csmith@gabrailcancercenter.com · 330-417-8231
    Contact: Study coordinator (Kim Roby) · kroby@gabrailcancercenter.com · 330.492.3345
    Contact: Principal Investigator (Nashat Gabrail, MD)
  • Oncology_Hematology Care Clinical Trials, LLC, Cincinnati, Ohio, United States

    Contact: Study coordinator (Douglas Hart) · douglas.hart@usoncology.com
    Contact: Principal Investigator (David M Waterhouse, MD)
  • Oncology_Hematology Care Clinical Trials, LLC, Cincinnati, Ohio, United States

    Contact: Study coordinator (Douglas Hart) · douglas.hart@usoncology.com
    Contact: Principal Investigator (David M Waterhouse, MD)
  • Oncology_Hematology Care Clinical Trials, LLC, Cincinnati, Ohio, United States

    Contact: Study coordinator (Douglas Hart) · douglas.hart@usoncology.com
    Contact: Principal Investigator (David M Waterhouse, MD)
  • Oncology_Hematology Care Clinical Trials, LLC, Cincinnati, Ohio, United States

    Contact: Study coordinator (Douglas Hart) · douglas.hart@usoncology.com
    Contact: Principal Investigator (David M Waterhouse, MD)
  • Oncology_Hematology Care Clinical Trials, LLC, Fairfield, Ohio, United States

    Contact: Study coordinator (Douglas Hart) · douglas.hart@usoncology.com
    Contact: Principal Investigator (David M Waterhouse, MD)
  • Willamette Valley Cancer Institute (Oregon), Eugene, Oregon, United States

    Contact: Study coordinator (Jeanne Schaffer) · jeanne.schaffer@usoncology.com
    Contact: Principal Investigator (Bo Wang, MD)
  • Northwest Cancer Specialists, P.C., Portland, Oregon, United States

    Contact: Study coordinator (Jennifer Thompson) · Jennifer.Thompson@usoncology.com
    Contact: Principal Investigator (Anthony Van Ho, MD)
  • Providence Cancer Institute, Portland, Oregon, United States

    Contact: Study coordinator (Brenda Fisher, RN) · canrsrchstudies@providence.org · 503-215-1979
    Contact: Principal Investigator (Rachel Sanborn, MD)
  • Northwest Cancer Specialists, P.C., Portland, Oregon, United States

    Contact: Study coordinator (Jennifer Thompson) · Jennifer.Thompson@usoncology.com
    Contact: Principal Investigator (Anthony Van Ho, MD)
  • Northwest Cancer Specialists, P.C., Tigard, Oregon, United States

    Contact: Study coordinator (Jennifer Thompson) · Jennifer.Thompson@usoncology.com
    Contact: Principal Investigator (Anthony Van Ho, MD)
  • Texas Oncology - DFW, Dallas, Texas, United States

    Contact: Study coordinator (Christine Terraciano) · Christine.terraciano@usoncology.com
    Contact: Principal Investigator (Kartik Konduri, MD)
  • Texas Oncology - Northeast Texas, Tyler, Texas, United States

    Contact: Study coordinator (Shelly Maxfield) · shelly.maxfield@usoncology.com
    Contact: Principal Investigator (Donald A Richards, MD)
  • Virginia Cancer Specialists, PC, Fairfax, Virginia, United States

    Contact: Study coordinator (Carrie Friedman) · carrie.friedman@usoncology.com
    Contact: Principal Investigator (Alexander I Spira, MD)
  • Northwest Cancer Specialists, P.C., Vancouver, Washington, United States

מובילי המחקר
  • Mark S Berger, MD

    Study Director

    Genprex, Inc.